If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

"We’re in very different place," the CEO of Editas says, citing the CRISPR pioneer's plans to get its first treatments into ...

Intellia Therapeutics, Inc. NTLA lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio ...

Researchers at the Experimental and Clinical Research Center in Berlin are developing a targeted treatment for muscular ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

CRISPR Therapeutics is a mid-stage biotech specializing in gene editing. It became the first gene-editing treatment that uses the Nobel Prize-winning CRISPR technique, an impressive achievement by ...

Findings from a multi-institutional, international study led by researchers from the Mayo Clinic Comprehensive Cancer Center have significantly advanced the understanding of genetic alterations in the ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...